Baseline characteristics of patients with CMML and with CMML-derived AML
| Characteristic . | No. . |
|---|---|
| No. of patients | 72 |
| Sex | |
| Male | 48 |
| Female | 24 |
| Age, y | |
| Median | 70 |
| Range | 38-89 |
| Metaphase cytogenetics (MC) | |
| Normal | 39 |
| Abnormal | 30 |
| No growth by MC | 3 |
| SNP-A karotyping | 70 |
| Clinical data not available | 2 |
| WHO classification | |
| CMML-1 | 36 |
| CMML-2 | 16 |
| sAML to CMML-1/2 | 20 |
| Characteristic . | No. . |
|---|---|
| No. of patients | 72 |
| Sex | |
| Male | 48 |
| Female | 24 |
| Age, y | |
| Median | 70 |
| Range | 38-89 |
| Metaphase cytogenetics (MC) | |
| Normal | 39 |
| Abnormal | 30 |
| No growth by MC | 3 |
| SNP-A karotyping | 70 |
| Clinical data not available | 2 |
| WHO classification | |
| CMML-1 | 36 |
| CMML-2 | 16 |
| sAML to CMML-1/2 | 20 |
WHO indicates World Health Organization.